Cilostazol as adjuvant therapy to Sertraline in major depressio

Phase 2

Not yet recruiting

• Conditions: Major Depressive Disorder.; Major depressive disorder, single episode, severe without psychotic features; F32.2

• Registration Number: IRCT20090117001556N130
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Based on DSM-5 diagnostic criteria, have major depression disorder
Based on Hamilton depression scale, get the minimum score of 19
Age between 18 to 65 years old

Exclusion Criteria

Serious suicidal thoughts (The score of >2 in Hamilton depression scale, the suicidal tendencies section)
Be psychosis
Concomitant psychiatric disorders in axis 1 such as bipolar disorder, schizophrenia, alcohol and substance abuse disorders
Concomitant psychiatric disorders in axis 2 such as personality disorder
History of hypomania and mania
History of Electroconvulsive therapy, two months prior to the trial
Presence of Thyroid disorder
Presence of cardiovascular disorder
Diabetes
Autoimmune disorder
Cancer
Presence of neurological disorders such as epilepsy, cerebral stroke, and dementia
Kidney and liver disorders
Pregnant or lactating women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of depression. Timepoint: Baseline and weeks 2, 4, and 8. Method of measurement: By Hamilton depression scale.